Search Results

Showing 85 results

Taxonomy / Categories

iwCLL 2025

Congress Year

International Workshop on CLL 2025

CLL

Disease Area

CLL/SLL

Disease Area

CLL

Congress Disease State

CLL/SLL

Congress Disease State

R/R CLL

Congress Disease State

Treatment Naive CLL/SLL

Congress Disease State

Bruton tyrosine kinase (BTK) degrader BGB-16673 in BTK inhibitor–naive patients with CLL/SLL and other B-cell malignancies: Results from the Phase 1 CaDAnCe-101 study

Congress Resource

Slides Download – Navigating treatment selection and infection management in CLL

Congress Resource

Real-world treatment and survival outcomes for zanubrutinib (zanu) and acalabrutinib (acala) monotherapy among treatment-naïve patients with chronic lymphocytic leukemia (CLL) in the United States

Congress Resource

Real-world impact of atrial fibrillation (AFib) on cardiovascular (CV) outcomes and healthcare resource utilization (HCRU) in patients with chronic lymphocytic leukemia (CLL)

Congress Resource

Real-world outcomes among Medicare beneficiaries treated with first-line (1L) Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL)

Congress Resource

Subsequent therapies and time to second progression-free survival events (PFS2) in treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (TN CLL/SLL) previously treated with zanubrutinib (zanu) or bendamustine-rituximab (BR) in SEQUOIA

Congress Resource

Sonrotoclax (BGB-11417) + zanubrutinib (SZ) vs venetoclax + acalabrutinib (AV) in treatment-naive chronic lymphocytic leukemia (TN CLL): A Phase 3 randomized trial design (CELESTIAL-TNCLL-2)

Congress Resource

First-line treatment of CLL/SLL with the all-oral combination of sonrotoclax (sonro) and zanubrutinib (zanu) achieves undetectable minimal residual disease (uMRD) rates of >90%, including in patients with del(17p)/TP53

Congress Presentation

First-line treatment of CLL/SLL with the all-oral combination of sonrotoclax (sonro) and zanubrutinib (zanu) achieves undetectable minimal residual disease (uMRD) rates of >90%, including in patients with del(17p)/TP53

Sonrotoclax (BGB-11417) + zanubrutinib (SZ) vs venetoclax + acalabrutinib (AV) in treatment-naive chronic lymphocytic leukemia (TN CLL): A phase 3 randomized trial design (CELESTIAL-TNCLL-2)

Congress Presentation

Sonrotoclax (BGB-11417) + zanubrutinib (SZ) vs venetoclax + acalabrutinib (AV) in treatment-naive chronic lymphocytic leukemia (TN CLL): A phase 3 randomized trial design (CELESTIAL-TNCLL-2)

Real-world outcomes among Medicare beneficiaries treated with first-line (1L) Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL)

Congress Presentation

Real-world outcomes among Medicare beneficiaries treated with first-line (1L) Bruton tyrosine kinase inhibitors (BTKis) for chronic lymphocytic leukemia (CLL)

You are now leaving the website

This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.

This link will take you to a third-party website outside of beonemedaffairs.com.

[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.

By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.

Do you want to leave beonemedaffairs.com

You are now leaving the the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed